Arrowhead Pharmaceuticals Presents Interim Results of ARO-INHBE Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2026
0mins
Arrowhead Pharmaceuticals presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis. The data presented at the European Association for the Study of the Liver Congress demonstrate that ARO-INHBE treatment led to clinically meaningful reductions in liver fat as a monotherapy and in combination with low-dose tirzepatide, a GLP-1/GIP receptor co-agonist, in adults with obesity. Arrowhead is currently engaging with regulatory authorities on additional designs and endpoints for potential Phase 2 studies in MASH and obesity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 81.040
Low
35.00
Averages
82.00
High
110.00
Current: 81.040
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arrowhead Pharmaceuticals Announces 2026 R&D Webinar Series
- 2026 Summer Webinar Series: Arrowhead Pharmaceuticals plans to host a series of R&D webinars in 2026, focusing on multiple clinical-stage RNA interference medicines utilizing its proprietary TRiM™ platform, aimed at enhancing market awareness in RNA therapeutics.
- Cardiometabolic Pipeline Focus: The first webinar is scheduled for June 29, 2026, concentrating on the cardiometabolic pipeline, featuring a keynote presentation by Dr. Steven Nissen from the Cleveland Clinic, showcasing Arrowhead's latest advancements in cardiovascular disease treatment.
- Diverse Agenda: Each webinar will last 60 to 90 minutes, covering Arrowhead's technology and R&D processes, clinical candidates, and discussions on relevant disease areas, designed to attract the attention of investors and healthcare professionals.
- Enhanced Market Engagement: Through these webinars, Arrowhead will provide live webcasts and replays, further enhancing interaction with investors and increasing the company's transparency and credibility in the biopharmaceutical industry.
See More
Arrowhead Pharmaceuticals to Participate in Upcoming Healthcare Conferences
- Conference Participation: Arrowhead Pharmaceuticals is scheduled to participate in the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 8:10 AM EDT, showcasing its advancements in RNA interference, which is expected to attract investor interest and enhance the company's visibility.
- Key Presentations: The company will also present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 9:00 AM EDT, highlighting its RNAi therapeutic solutions for intractable diseases, potentially fostering communication and collaboration with prospective partners.
- Platform Advantage: Arrowhead leverages its industry-leading TRiM™ platform to develop RNAi therapeutics that can precisely target various cell types, which is anticipated to enhance its competitiveness in clinical and commercial arenas while addressing significant unmet medical needs.
- Investor Relations: Presentation materials and webcast links will be accessible via the investor section of the company's website, aiming to strengthen communication with investors, enhance transparency, and attract more investor attention.
See More
Arrowhead Pharmaceuticals Presents New Clinical Data for Plozasiran at EAS Congress
- Clinical Data Support: Arrowhead Pharmaceuticals presented new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, indicating its use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment, highlighting the drug's importance in addressing patient needs.
- Safety Assessment: Despite modest increases in plozasiran exposure among patients with moderate-to-severe renal or moderate hepatic impairment, pharmacodynamic responses (APOC3 and triglyceride reduction) were similar to control cohorts, indicating good safety and tolerability of the drug in these populations.
- Pregnancy Impact: A case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of triglyceride levels throughout pregnancy, providing new insights into the drug's application in special populations, although further data are needed to confirm its safety and efficacy.
- Future Research Directions: Arrowhead plans to conduct additional trials to further evaluate the safety of plozasiran in patients with liver or renal disease, underscoring the company's commitment to developing innovative therapies for unmet medical needs.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
- Prescription Growth: Arrowhead Pharmaceuticals has written over 400 prescriptions since the launch of REDEMPLO, with approximately 30 new prescriptions each week, indicating strong market demand and product acceptance, which is expected to drive future revenue growth.
- Pricing Strategy Adjustment: The U.S. wholesale acquisition cost for REDEMPLO has been reduced from $60,000 to $45,000 per year, aimed at expanding market coverage, particularly for patients with high triglycerides, potentially enhancing market share and competitiveness.
- Strong Financial Position: As of March 31, 2026, Arrowhead reported nearly $1.8 billion in cash and investments, demonstrating robust financial strength to support future R&D and market expansion plans.
- Clinical Trial Progress: Top-line data from the SHASTA-3 and SHASTA-4 studies are expected to be released in Q3, with plans to file a supplemental new drug application with the FDA by the end of 2026, which could provide new growth momentum for the company.
See More
Arrowhead Pharmaceuticals Announces 2026 R&D Webinar Series
- 2026 Summer Webinar Series: Arrowhead Pharmaceuticals plans to host a series of R&D webinars in 2026, focusing on multiple clinical-stage RNA interference medicines utilizing its proprietary TRiM™ platform, aimed at enhancing market awareness in RNA therapeutics.
- Cardiometabolic Pipeline Focus: The first webinar is scheduled for June 29, 2026, concentrating on the cardiometabolic pipeline, featuring a keynote presentation by Dr. Steven Nissen from the Cleveland Clinic, showcasing Arrowhead's latest advancements in cardiovascular disease treatment.
- Diverse Agenda: Each webinar will last 60 to 90 minutes, covering Arrowhead's technology and R&D processes, clinical candidates, and discussions on relevant disease areas, designed to attract the attention of investors and healthcare professionals.
- Enhanced Market Engagement: Through these webinars, Arrowhead will provide live webcasts and replays, further enhancing interaction with investors and increasing the company's transparency and credibility in the biopharmaceutical industry.
See More
Arrowhead Pharmaceuticals to Participate in Upcoming Healthcare Conferences
- Conference Participation: Arrowhead Pharmaceuticals is scheduled to participate in the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 8:10 AM EDT, showcasing its advancements in RNA interference, which is expected to attract investor interest and enhance the company's visibility.
- Key Presentations: The company will also present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 9:00 AM EDT, highlighting its RNAi therapeutic solutions for intractable diseases, potentially fostering communication and collaboration with prospective partners.
- Platform Advantage: Arrowhead leverages its industry-leading TRiM™ platform to develop RNAi therapeutics that can precisely target various cell types, which is anticipated to enhance its competitiveness in clinical and commercial arenas while addressing significant unmet medical needs.
- Investor Relations: Presentation materials and webcast links will be accessible via the investor section of the company's website, aiming to strengthen communication with investors, enhance transparency, and attract more investor attention.
See More
Arrowhead Pharmaceuticals Presents New Clinical Data for Plozasiran at EAS Congress
- Clinical Data Support: Arrowhead Pharmaceuticals presented new clinical data for plozasiran at the 94th European Atherosclerosis Society Congress, indicating its use in patients with moderate-to-severe renal or moderate hepatic impairment without dose adjustment, highlighting the drug's importance in addressing patient needs.
- Safety Assessment: Despite modest increases in plozasiran exposure among patients with moderate-to-severe renal or moderate hepatic impairment, pharmacodynamic responses (APOC3 and triglyceride reduction) were similar to control cohorts, indicating good safety and tolerability of the drug in these populations.
- Pregnancy Impact: A case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of triglyceride levels throughout pregnancy, providing new insights into the drug's application in special populations, although further data are needed to confirm its safety and efficacy.
- Future Research Directions: Arrowhead plans to conduct additional trials to further evaluate the safety of plozasiran in patients with liver or renal disease, underscoring the company's commitment to developing innovative therapies for unmet medical needs.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
- Prescription Growth: Arrowhead Pharmaceuticals has written over 400 prescriptions since the launch of REDEMPLO, with approximately 30 new prescriptions each week, indicating strong market demand and product acceptance, which is expected to drive future revenue growth.
- Pricing Strategy Adjustment: The U.S. wholesale acquisition cost for REDEMPLO has been reduced from $60,000 to $45,000 per year, aimed at expanding market coverage, particularly for patients with high triglycerides, potentially enhancing market share and competitiveness.
- Strong Financial Position: As of March 31, 2026, Arrowhead reported nearly $1.8 billion in cash and investments, demonstrating robust financial strength to support future R&D and market expansion plans.
- Clinical Trial Progress: Top-line data from the SHASTA-3 and SHASTA-4 studies are expected to be released in Q3, with plans to file a supplemental new drug application with the FDA by the end of 2026, which could provide new growth momentum for the company.
See More
